Items where authors include "Hicks, A."

Article

Abani, O., Abbas, A., Abbas, F. et al. (7724 more authors) (2025) Sotrovimab versus usual care in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet Infectious Diseases. ISSN 1473-3099

Abani, O., Abbas, A., Abbas, F. et al. (8041 more authors) (2025) Molnupiravir or nirmatrelvir–ritonavir plus usual care versus usual care alone in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet Infectious Diseases. ISSN 1473-3099

Abani, O., Abbas, A., Abbas, F. et al. (8021 more authors) (2025) Higher dose corticosteroids in hospitalised COVID-19 patients requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial. eClinicalMedicine, 81. 103080. ISSN 2589-5370

Abani, O., Abbas, A., Abbas, F. et al. (8021 more authors) (2025) Higher dose corticosteroids in hospitalised COVID-19 patients requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial. EClinicalMedicine, 81. 103080. ISSN 2589-5370

Isham, L. orcid.org/0000-0003-1752-5236, Loe, B.S., Hicks, A. et al. (3 more authors) (2024) Daydreaming and grandiose delusions: development of the Qualities of Daydreaming Scale. Behavioural and Cognitive Psychotherapy, 52 (3). pp. 262-276. ISSN 1352-4658

Faust, S.N., Haynes, R., Jones, C.E. et al. (7370 more authors) (2024) Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet Child & Adolescent Health, 8 (3). pp. 190-200. ISSN 2352-4642

Faust, S.N., Haynes, R., Jones, C.E. et al. (7370 more authors) (2024) Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet Child & Adolescent Health, 8 (3). pp. 190-200. ISSN 2352-4642

Abani, O., Abbas, A., Abbas, F. et al. (7989 more authors) (2023) Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet Diabetes & Endocrinology, 11 (12). pp. 905-914. ISSN 2213-8587

Hicks, A., McKinney, P. orcid.org/0000-0002-0227-3534, Inskip, C. et al. (2 more authors) (2023) Leveraging information literacy: mapping the conceptual influence and appropriation of information literacy in other disciplinary landscapes. Journal of Librarianship and Information Science, 55 (3). pp. 548-566. ISSN 0961-0006

Isham, L., Loe, B.S., Hicks, A. et al. (3 more authors) (2023) The difficulties of grandiose delusions: harms, challenges, and implications for treatment engagement. Schizophrenia Bulletin, 49 (5). pp. 1194-1204. ISSN 0586-7614

Abani, O., Abbas, A., Abbas, F. et al. (8104 more authors) (2023) Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet, 401 (10387). pp. 1499-1507. ISSN 0140-6736

Liu, X., Munro, A.P., Feng, S. et al. (56 more authors) (2023) Corrigendum to “Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial” [J Infect 84(6) (2022) 795–813, 5511]. Journal of Infection, 86 (5). pp. 540-541. ISSN 0163-4453

Isham, L., Sheng Loe, B., Hicks, A. et al. (4 more authors) (2022) The meaning in grandiose delusions: measure development and cohort studies in clinical psychosis and non-clinical general population groups in the UK and Ireland. The Lancet Psychiatry, 9 (10). pp. 792-803. ISSN 2215-0366

Munro, A.P.S., Feng, S., Janani, L. et al. (362 more authors) (2022) Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial. The Lancet Infectious Diseases, 22 (8). pp. 1131-1141. ISSN 1473-3099

Liu, X., Munro, A.P.S., Feng, S. et al. (56 more authors) (2022) Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial. Journal of Infection, 84 (6). pp. 795-813. ISSN 0163-4453

Isham, L., Griffith, L., Boylan, A. et al. (6 more authors) (2021) Understanding, treating, and renaming grandiose delusions : a qualitative study. Psychology and Psychotherapy: Theory, Research and Practice, 94 (1). papt.12260. pp. 119-140. ISSN 1476-0835